FDA Adverse Event Injury Summary report: N

INTRALASE FS2

MDR report key: 5793010 · Received July 13, 2016

Report

Report Number
3006695864-2016-00713
Event Type
Injury
Date Received
July 13, 2016
Date of Event
June 3, 2016
Report Date
July 13, 2016
Manufacturer
ABBOTT MEDICAL OPTICS
Product Code
HNO
PMA / PMN Number
K060372
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
WI, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4). THE LASER MACHINE WAS EXAMINED AND TESTED BY AN AMO FIELD SERVICE SPECIALIST (FSS). THE FSS FOUND NO ISSUES WITH THE LASER. THE FSS PERFORMED A 3 MONTH PREVENTATIVE MAINTENANCE. IN ADDITION, THE FSS CHECKED THE AUTOCORRELATION, SPOT CAMERA DATA AND OSCILLATOR BI-STABILITY REGION. THE FSS PERFORMED A FIELD SERVICE CHECKLIST. THE SYSTEM WAS VERIFIED FOR ALL MODES OF OPERATIONS AND CALIBRATIONS. THE SYSTEM MET AMO SPECIFICATIONS. ALL PERTINENT INFORMATION AVAILABLE TO ABBOTT MEDICAL OPTICS HAS BEEN SUBMITTED.

Description of Event or Problem · 1

THE SURGERY CENTER REPORTED THAT A LASER VISION CORRECTION PATIENT EXPERIENCED DIFFUSE LAMELLAR KERATITIS (DLK) POSSIBLE STAGE 4 ON THE BOTH EYES (OU) AFTER A LASER PROCEDURE THAT WAS PERFORMED IN (B)(6) 2016. A DESCRIPTION FROM THE SURGERY CENTER INDICATED THE SURGEON WAS SEEING PERIPHERAL LAMELLAR INFLAMMATION FOR ABOUT 2 WEEKS. THE SURGEON STATED THE INFLAMMATION RESPONDS TO INCREASE IN STEROID DROPS. IN ADDITION, THE SURGEON DECREASED THE ENERGY FROM .80 BED ENERGY TO .75 BED ENERGY. AN ABBOTT MEDICAL OPTICS' APPLICATION SUPPORT MANAGER (ASM) DISCUSSED THE INFLAMMATION COULD ALSO BE DUE TO EXTERNAL SOURCES, SUCH AS INSTRUMENTAL CLEANING AND STERILIZATION, EYE DROPS AND GLOVE USE. AT ONE DAY POST OP, THE PATIENT HAD AN INCREASE IN ANTIBIOTICS (VIGAMOX) AND STEROIDS-PRED FORTE (PF) WAS STARTED FOR 6 DAYS. AT 8 DAY POST OP EXAM, THE RIGHT EYE (OD) WAS RESOLVED AND THE LEFT EYE STILL HAD DLK PRESENT AND HAD A LOSS OF BEST CORRECTED VISUAL ACUITY, THE PF WAS TO BE CONTINUED FOR 4 DAYS. ON 12 DAY POST OP EXAM, THE OS HAD 50 % IMPROVEMENT AND PF WAS TO BE CONTINUED FOR THE NEXT 10 DAYS. THIS IS THREE OF FOUR REPORTS. PRE-OP BCVA OU FROM (B)(6) 2016 20/15-. POST-OP BCVA OS FROM (B)(6) 2016: 20/30+1. POST-OP BCVA OS FROM (B)(6) 2016: 20/15. POST-OP BCVA OS FROM (B)(6) 2016: 20/30+2.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
445407 INTRALASE FS2 FEMTOSECOND LASER HNO ABBOTT MEDICAL OPTICS 20003

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention